Stocks · News reference
Humacyte Confirms Plans For ATEV Supplemental BLA Filing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 24, 2026, 12:03 PM
- Checked
- Aug 24, 2026, 1:28 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Humacyte Announces Publication Of One-Year V007 Phase 3 Results In The Lancet Digital Health Showing ATEV Superiority Over Autogenous Fistula For Hemodialysis Access
Read original at benzingaHumacyte Announces Symvess Acellular Tissue Engineered Vessel-Tyod Now Being Used By Arizona Surgeons
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that Symvess, acellular tissue engineered vessel-tyod, is now being used by surgeons in
Read original at benzinga